La PMCB combina l’analisi di dati, tecnologie avanzate, patologia digitale, genomica funzionale e screening ad alto rendimento per approfondire la comprensione dell’eziologia delle malattie a livello cellulare e molecolare, identificare nuovi bersagli, elaborare strategie per stratificare i pazienti, accrescere in efficienza la pipeline. de Rinaldis ha maturato una vasta esperienza in ambito accademico, biotecnologico e farmaceutico, scoprendo e applicando la biologia dei sistemi e il sequenziamento per identificare terapie di medicina di precisione in oncologia e immunologia. Più di 60 gli articoli su riviste peer-reviewed ad alto impatto: Nature, Nature Genetics, Nature Communications, Human Molecular Genetics, Blood, Lancet e altre. In Sanofi dal 2017, prima è stato responsabile Bioinformatica traslazionale e docente senior onorario al King’s College di Londra/BRC (NHS), scienziato senior in Merck MRL e ingegnere scientifico del software e Group Leader in Lion Bioscience AG.
PMCB combines use of data, advanced analytics, digital pathology, functional genomics, and high-throughput profiling technologies for a deeper understanding of disease etiology at cellular and molecular level, the translation of these findings into novel target hypotheses and strategies for patient stratification, to increase pipeline success and pace. de Rinaldis has extensive experience in academia, biotech, pharmaceuticals, discovering and applying systems biology, and high-throughput technologies, to enable precision medicine therapies in oncology and immunology. He published > 60 articles in high-impact peer-reviewed journals: Nature, Nature Genetics, Nature Communications, Human Molecular Genetics, Blood, Lancet and others. Prior to joining Sanofi (in 2017), he was the Head of Translational Bioinformatics and an Honorary Senior Lecturer at King’s College of London/BRC (NHS), Senior Scientist at Merck MRL and a Scientific Software Engineer and Group Leader at Lion Bioscience AG.